Human Embryonic Stem Cell-derived M Cell

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.


Generic Name
Human Embryonic Stem Cell-derived M Cell
DrugBank Accession Number

CAStem is composed of immunity- and matrix-regulatory cells (IMRCs), also known as M cells, which can be administered through injection. These IMRCs are differentiated from human embryonic stem cells that are expanded and then harvested. These cells are currently being investigated against lung injury and fibrosis -- conditions which are outcomes of lung disorders including COVID-19. IMRCs are similar to MSCs in terms of their capacity for self-renewal and tri-lineage differentiation. However, the difference comes with IMRCs displaying a higher quality of consistency, having stronger immunomodulatory and anti-fibrotic functions, and being stronger in potential treatment of lung injury and fibrosis.

Biologic Classification
Cell transplant therapies
Other cell transplant therapies
  • CAStem
  • immunity- and matrix-regulatory cells
  • Immunity-and-matrix-regulatory cells
  • IMRCs
  • M cells
External IDs
  • Human Embryonic Stem Cell-derived M Cell



Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more

Not Available

Mechanism of action

IMRCs are different from cells such as the umbilical cord mesenchymal stem cells in gene expression profile; thus, this results in IMRCs possessing qualities such as higher expression levels of proliferative, immunomodulatory, and anti-fibrotic genes. Additionally, they have the ability to modulate immunity and regulate extracellular matrix production.


Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Not Available
Route of elimination

Not Available


Not Available


Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample

Not Available

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available


Drug Categories
Not Available
Not classified
Affected organisms
Not Available

Chemical Identifiers

Not Available
CAS number
Not Available


General References
  1. Wu J, Song D, Li Z, Guo B, Xiao Y, Liu W, Liang L, Feng C, Gao T, Chen Y, Li Y, Wang Z, Wen J, Yang S, Liu P, Wang L, Wang Y, Peng L, Stacey GN, Hu Z, Feng G, Li W, Huo Y, Jin R, Shyh-Chang N, Zhou Q, Wang L, Hu B, Dai H, Hao J: Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis. Cell Res. 2020 Jun 16. pii: 10.1038/s41422-020-0354-1. doi: 10.1038/s41422-020-0354-1. [Article]
Not Available

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
1, 2Unknown StatusTreatmentAcute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19) / Lung Injury, Acute (ALI) / Virus; Pneumonia1somestatusstop reasonjust information to hide
0Not Yet RecruitingTreatmentGastric Cancer1somestatusstop reasonjust information to hide


Not Available
Not Available
Dosage Forms
Not Available
Not Available
Not Available


Not Available
Experimental Properties
Not Available

Drug created at August 11, 2020 20:11 / Updated at August 13, 2020 07:02